Relapsing Fever in Refugees: What You Need to Know
"Understanding the risks, diagnosis, and management of louse-borne relapsing fever (LBRF) in vulnerable populations."
A recent letter to the editor has sparked an important discussion regarding relapsing fever, particularly in young refugees from East Africa. This condition, often caused by co-infections like Leptospira spp. and Borrelia recurrentis, poses significant diagnostic and treatment challenges. Understanding the nuances of this disease is crucial for healthcare providers serving vulnerable populations.
One key point of contention revolves around the vectors of louse-borne relapsing fever (LBRF). While body lice (Pediculus humanus humanus) are the primary culprits, the role of head lice (Pediculus humanus capitis) is less clear. Some studies suggest head lice might play a role, but definitive evidence remains limited, emphasizing the need for careful examination and differentiation.
The clinical presentation of LBRF can be severe, mimicking other conditions and complicating diagnosis. Symptoms like shock, acute respiratory distress syndrome (ARDS), renal failure, and jaundice can arise from either Leptospira or Borrelia infections. Recognizing the potential for LBRF, especially in individuals with a history of displacement, is essential for prompt and accurate treatment.
Refugee Health Data and Evidence
A review of long-term physical health outcomes examined U.S. resettlement studies published from 2008–2018, focusing on Burmese, Iraqi, Bhutanese, Somali, and Congolese refugees, as well as studies with unspecified refugee populations. It included outcomes measured beyond the first eight months after arrival. UNHCR’s Refugee Data app presents forced-displacement and statelessness statistics by country of asylum and origin over the last 24 years. The supplied sources do not provide a specific relapsing-fever case count or prevalence estimate among refugees.
Diagnosis and Prevention of LBRF
The CDC says louse-borne relapsing fever (LBRF) occurs in regions of Africa and is extremely unlikely in the United States without travel to an endemic region. In symptomatic, untreated patients early in infection, clinicians can diagnose it by directly visualizing spirochetes in a peripheral blood smear. The CDC also describes regular changes of clothing and bedding and hot-water showers as prevention measures. A 2021 systematic review characterizes LBRF as an epidemic disease associated historically with forced migration and crowded, poor-hygiene conditions.
A Two-Millennia History
The American Society for Microbiology reports that relapsing fever has been known for more than 2,000 years, with the first known description written by Hippocrates in 430 B.C. A causative species was identified in 1886, and tick transmission was demonstrated in 1904. The disease caused major outbreaks in the first half of the 20th century that affected more than 60 million people. Relapsing fever is caused by Borrelia species and features recurring bouts of fever separated by periods of relative health.
Decoding LBRF: Key Considerations for Diagnosis and Management
Diagnosing LBRF requires a keen awareness of its subtle presentations and potential for relapse. Molecular biology techniques, such as real-time polymerase chain reaction (PCR), are invaluable for accurate identification of the causative agents. However, it's also crucial to consider the possibility of previous, overlooked infections, especially when language barriers and incomplete medical histories exist.
- Vector Clarification: Body lice are the primary vectors of LBRF, though head lice might play a role in some instances.
- Clinical Overlap: Symptoms can mimic other infections, necessitating careful evaluation.
- Diagnostic Tools: PCR is crucial for accurate diagnosis.
- Relapse Awareness: Consider the possibility of previous, undiagnosed infections.
- Increased Vigilance: Intensivists should be aware of the rising prevalence of LBRF in migrant populations.
Research Gaps in Relapsing Fever
A narrative review published September 18, 2026, surveys existing knowledge of relapsing-fever ecology, epidemiology, diagnostics, disease, and prevention, and identifies areas needing further research. A separate review assessed research on 40 clinically relevant zoonotic pathogens among refugees, internally displaced people, and asylum seekers worldwide. Its stated aim was to evaluate the state of research on those selected pathogens; the supplied summary does not specify relapsing-fever-specific findings. These sources therefore point to review activity but do not establish new refugee-specific relapsing-fever estimates in the provided material.
Missed Recognition in Clinical Guidance
A report on young refugees from East Africa cautions that intensivists should be aware of LBRF, noting that it was not mentioned in a review on diagnosing and managing critically ill migrants. This highlights a potential gap in awareness rather than evidence that LBRF is absent from refugee health. The CDC says U.S. domestic refugee medical screening usually takes place 30–90 days after arrival, and its malaria guidance is intended to support initial screening and disease prevention. The supplied sources do not establish whether this screening schedule detects LBRF reliably.
Interpreting Scalp Findings
A commentary on a reported case of severe Leptospira and Borrelia recurrentis coinfection in a young female refugee from East Africa focuses on the description that “nits were present on her scalp.” The authors argue that this wording may mislead readers about what the finding means. The supplied excerpt does not provide the full explanation or enough detail to compare diagnostic performance or treatment outcomes. It does show that interpretation of clinical observations in an individual refugee case can be contested.
Moving Forward: A Collaborative Approach to LBRF
The complexities surrounding LBRF in refugee populations highlight the need for a collaborative and informed approach. Healthcare providers must remain vigilant, considering LBRF in their differential diagnoses, especially when faced with patients presenting with fever, shock, and a history of displacement. Overcoming language barriers and obtaining thorough medical histories are paramount.
Re-emergence Among East African Asylum Seekers
A 2016 review describes LBRF as a neglected and forgotten disease that had recently re-emerged among East African migrants seeking asylum in Europe. It reviews observed cases and reassesses questions about clinical presentation, diagnosis, and treatment. A related source identifies asylum seekers from the Horn of Africa arriving in Europe after prolonged stays in refugee camps in Libya as a group in whom LBRF was increasingly observed. It also says a sepsis-like presentation associated with thrombocytopenia should prompt clinical suspicion.
Mapping Relapsing-Fever Risk
A 2024 study aimed to map the diversity, global distribution, and potential infection risk of relapsing-fever-group Borrelia (RFGB). It highlights emerging species such as Borrelia miyamotoi and says their global distribution and associated risk burden remain uncertain. The study’s stated goal is to improve understanding of those patterns, rather than to report a settled global risk estimate. Separately, the GIDS page describes surveillance data across three countries from January 1, 1980, to September 6, 2026, with case trends, source metadata, and downloadable records.
Challenges in Migrant and Refugee Health
A 2019 report developed a framework for reflecting on challenges and solutions in migrant and refugee health. It was shaped by discussions at the second M8 Alliance Expert Meeting, held at Sapienza University of Rome on June 15–16, 2018, and supplemented by literature. The supplied summary does not name specific challenges or describe relapsing fever directly. It places the topic within a broader effort to address migrant and refugee health through discussion and evidence.
Increased awareness and education are essential for improving outcomes. By fostering collaboration between specialists and utilizing advanced diagnostic tools, we can ensure timely and accurate diagnoses. This, in turn, leads to more effective treatment and reduces the risk of severe complications.
Ultimately, addressing LBRF in vulnerable populations requires a multi-faceted approach that combines medical expertise with a commitment to providing compassionate and culturally sensitive care. By working together, we can improve the health and well-being of refugees and other at-risk individuals.